Dr. Abbey Spoke About Vitrectomy and Light Adjustable Lenses at ASRS 2026
Texas Retina’s Ashkan Abbey, MD, FASRS, FAAO, participated in a panel discussion on the impact of vitrectomy on light adjustable lenses before final laser lock-in in post-cataract surgery patients at the 44th
read more
Dr. Abbey Publishes Article on Home OCT Monitoring for Wet AMD
Texas Retina’s Ashkan M. Abbey, MD, recently published an article exploring how home optical coherence tomography (OCT) monitoring may help detect recurring disease activity earlier in patients with neovascular (wet) age-related macular
read more Dr. Abbey Shares Clinical Insights on Management of Wet AMD
Texas Retina’s Dr. Ashkan Abbey recently discussed neovascular (wet) age-related macular degeneration (AMD) management on Vumedi, a video education and peer-to-peer learning platform for doctors and medical professionals. Dr. Abbey’s video presentation
read more Dr. Abbey Discusses the New Era of Geographic Atrophy Management
Texas Retina’s Ashkan M. Abbey, MD, recently participated in a three-part special report video series by Ophthalmology Times that examined the evolving treatment landscape for geographic atrophy (GA). What is Geographic Atrophy?
read more
Dr. Abbey Presented on Retinal Sustained Drug Delivery Research at Retina World Congress
At the recently held Retina World Congress 2026 meeting, Texas Retina’s Dallas Director of Clinical Research Ashkan M. Abbey, MD, presented on the evolving clinical trial landscape for sustained drug delivery in retinal disease. Dr.
read more Dr. Abbey Discusses Retinal Vein Occlusion as a Marker of Systemic Risk
Texas Retina’s Ashkan Abbey, MD, recently appeared on the ReachMD podcast to discuss “Retinal Vein Occlusion as a Marker of Systemic Risk.” This was the third episode he contributed to their “Eye
read more Dr. Abbey Discusses Retinal Vein Occlusion on ReachMD Podcast
Texas Retina’s Ashkan Abbey, MD, recently appeared on the ReachMD podcast as part of their “Spotlight on Retinal Vein Occlusion” series. In the first episode of this series, Dr. Abbey discusses distinguishing urgent
read more Dr. Abbey Publishes Case Report on New Approach to Treating Chronic Postoperative Cystoid Macular Edema
Texas Retina’s Ashkan Abbey, MD, recently collaborated with colleagues from the Department of Ophthalmology at University of Texas Southwestern Medical Center in Dallas, to publish a case report in Retinal Cases &
read more Dr. Abbey Discusses New Treatment for Macular Telangiectasia Type 2
At AAO 2025, the American Academy of Ophthalmology’s annual meeting, Texas Retina’s Dr. Ashkan Abbey moderated a case-based roundtable discussion about the evolving landscape of macular telangiectasia (MacTel) type 2 care, including
read more
Dr. Abbey Doses First Patient in Phase 1b/2a LOTUS-2 Clinical Trial of Novel Multivalent Fusion Antibody EB-105 for Diabetic Macular Edema
On October 28, 2025, Texas Retina Associates Director of Clinical Research for Dallas Ashkan Abbey, MD, dosed the first patient in the Phase 1b/2a LOTUS-2 clinical trial of novel multivalent fusion antibody (EB-105) for diabetic
read more